Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug hopes to stop liver scarring in its tracks

NCT ID NCT06920043

Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 2 trial tests a drug called efimosfermin alfa in 42 adults with liver scarring (cirrhosis) caused by fatty liver disease (MASH). Participants receive either the drug or a placebo as a shot under the skin. The main goal is to check safety and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
efimosfermin alfa (also called BOS-580)
What this could lead to
If successful, this could point toward a treatment to control MASH-related cirrhosis and prevent liver disease from worsening.
What could go wrong
This is a small, early-phase trial focused on safety, not on curing the disease. The drug may not show enough benefit or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 42 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to understand and sign a written informed consent form (ICF) * Age 18 through 75 years at enrollment * History or presence of 2 or more of the 5 components of metabolic syndrome * Liver biopsy confirmation of MASH consistent with stage F4 fibrosis * Other inclusion criteria may apply. Exclusion Criteria: * Individuals with chronic liver disease from other causes, or any history or evidence of decompensated liver disease * History of type 1 diabetes * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × the upper limit of normal (ULN) * Other exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic dysfunction-associated steatohepatitis Non-alcoholic fatty liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Chandler, Arizona, 85224, United States

  • GSK Investigational Site

    RECRUITING

    Mesa, Arizona, 85381, United States

  • GSK Investigational Site

    RECRUITING

    Tucson, Arizona, 85712, United States

  • GSK Investigational Site

    RECRUITING

    Fresno, California, 93720, United States

  • GSK Investigational Site

    RECRUITING

    Lancaster, California, 93534, United States

  • GSK Investigational Site

    RECRUITING

    Pasadena, California, 91105, United States

  • GSK Investigational Site

    RECRUITING

    Rialto, California, 92377, United States

  • GSK Investigational Site

    RECRUITING

    Santa Maria, California, 93458, United States

  • GSK Investigational Site

    RECRUITING

    Miami, Florida, 33156, United States

  • GSK Investigational Site

    RECRUITING

    Viera, Florida, 32940, United States

  • GSK Investigational Site

    RECRUITING

    Marietta, Georgia, 30060, United States

  • GSK Investigational Site

    RECRUITING

    Baltimore, Maryland, 21202, United States

  • GSK Investigational Site

    RECRUITING

    Kansas City, Missouri, 64131, United States

  • GSK Investigational Site

    RECRUITING

    New York, New York, 10029, United States

  • GSK Investigational Site

    RECRUITING

    Fayetteville, North Carolina, 28304, United States

  • GSK Investigational Site

    RECRUITING

    Wilson, North Carolina, 27612, United States

  • GSK Investigational Site

    RECRUITING

    Austin, Texas, 78745, United States

  • GSK Investigational Site

    RECRUITING

    Austin, Texas, 78757, United States

  • GSK Investigational Site

    RECRUITING

    Austin, Texas, 78757, United States

  • GSK Investigational Site

    RECRUITING

    Dallas, Texas, 75203, United States

  • GSK Investigational Site

    RECRUITING

    Georgetown, Texas, 78626, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77030, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77030, United States

  • GSK Investigational Site

    RECRUITING

    Houston, Texas, 77079, United States

  • GSK Investigational Site

    RECRUITING

    Pasadena, Texas, 77505, United States

  • GSK Investigational Site

    RECRUITING

    Pearland, Texas, 77584, United States

  • GSK Investigational Site

    RECRUITING

    San Antonio, Texas, 78215, United States

  • GSK Investigational Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • GSK Investigational Site

    RECRUITING

    Waco, Texas, 76710, United States

  • GSK Investigational Site

    RECRUITING

    Richmond, Virginia, 23249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.